CASC Insider Trading Activity and SEC Form 4 Filings
CASC insider trading summary
No open-market insider purchases or sales of Cascadian Therapeutics, Inc. (CASC) have been reported on SEC Form 4 in the past 12 months.
Latest CASC insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 11, 2017 | Scott Dunseth Myers | President and CEO | Buy | $21K (5,500 @ $3.73) |
| May 12, 2017 | Scott Dunseth Myers | President and CEO | Buy | $11K (2,800 @ $4.00) |
| Mar 31, 2017 | Scott Dunseth Myers | President and CEO | Buy | $8K (2,000 @ $4.11) |
| Mar 28, 2017 | Gwen A. Fyfe | Director | Buy | $7K (1,666 @ $4.12) |
| Mar 20, 2017 | Scott Dunseth Myers | President and CEO | Buy | $4K (1,000 @ $3.93) |
| Feb 2, 2017 | Ted W Love | Director | Buy | $98K (23,000 @ $4.24) |
| Jan 30, 2017 | Christopher S Henney | Director | Buy | $104K (25,324 @ $4.11) |
| Jan 27, 2017 | Scott Dunseth Myers | President and CEO | Buy | $77K (20,500 @ $3.76) |
| Aug 17, 2016 | Scott Dunseth Myers | President and CEO | Buy | $52K (45,000 @ $1.15) |
| Jun 28, 2016 | Scott Dunseth Myers | President and CEO | Buy | $50K (62,500 @ $0.80) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.